Clear Search

Showing 2 results for “Inman RD”.

February 2023

Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network

J Rheumatol. 2023 jrheum doi: 10.3899/jrheum.220824

The results of this real-world study of Canadian axSpA patients, the first of its kind, support the effectiveness of secukinumab for treatment of axSpA. This study aimed to use the CanSpA Research Network to describe real-world retention and effectiveness of secukinumab in the Canadian axSpA population.

more…

July 2022

Efficacy and Safety of Upadacitinib for Active Ankylosing Spondylitis Refractory to Biological Therapy: A Double-blind, Randomised, Placebo-controlled Phase 3 Trial

Ann Rheum Dis 2022 doi:10.1136/annrheumdis-2022-222608

Van der Heijde et al., carried out a study to show whether upadacitinib offers an effective treatment option for bDMARD-naïve and bDMARD-IR patients with active AS. Their results indicated that upadacitinib 15 mg significantly improved the signs and symptoms of active AS. The treatment was well tolerated for 14 weeks in bDMARD-IR patients, consistent with results observed in the upadacitinib AS bDMARD-naïve study.

more…